{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:28:25Z","timestamp":1786357705030,"version":"build-2736575974"},"reference-count":14,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Monoquant P\/L","award":["567.30485"],"award-info":[{"award-number":["567.30485"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Libraries for next-generation sequencing were prepared using primers directed to framework 2, framework 3 and D and the 6 J regions of the rearranged immunoglobulin gene from 50 diagnosis myeloma bone marrow samples. After sequencing and bioinformatic analysis, a marker sequence suitable for minimal residual disease analysis by HAT-PCR was obtained for 90% of the 50 samples studied. In 88% of samples a complete VDJ sequence was obtained. Failure to detect a marker sequence was principally due to a low percentage of plasma cells in the marrow sample. Evaluation of 24 pairs of primers showed that they were highly specific and, when used in HAT-PCR, they provided accurate quantification. The high frequency of detection of a suitable marker sequence indicates that minimal residual disease can be monitored by HAT-PCR in the great majority of instances.<\/jats:p>","DOI":"10.3390\/ijms27167128","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:24:53Z","timestamp":1786353893000},"page":"7128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of Marker Immunoglobulin Rearrangements for Use by HAT-PCR in Myeloma"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3767-2758","authenticated-orcid":false,"given":"Elizabeth","family":"Hughes","sequence":"first","affiliation":[{"name":"College of Medicine and Public Health, Flinders University, Adelaide, SA 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-5508","authenticated-orcid":false,"given":"Alexander","family":"Morley","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University, Adelaide, SA 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: Evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: Analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2025.43.16_suppl.7503","article-title":"Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial","volume":"43","author":"Landgren","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: A head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_6","first-page":"2160","article-title":"Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: A prospective comparison study","volume":"110","author":"Yoroidaka","year":"2025","journal-title":"Haematologica"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ching, T., Duncan, M.E., Newman-Eerkes, T., McWhorter, M.M.E., Tracy, J.M., Steen, M.S., Brown, R.P., Venkatasubbarao, S., Akers, N.K., and Vignali, M. (2020). Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07077-9"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jmoldx.2022.03.007","article-title":"Sensitive Measurement of Minimal Residual Disease in Blood by HAT-PCR","volume":"24","author":"Latham","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Latham, S., Hughes, E., Budgen, B., and Morley, A. (2023). Inhibition of the PCR by genomic DNA. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0284538"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hughes, E., Latham, S., Kuss, B., Grist, S., Hall, R., Khong, T., Gorniak, M., Spencer, A., Tam, C., and Mulligan, S. (2025). HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167720"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bjh.70478","article-title":"HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma","volume":"208","author":"Hughes","year":"2026","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jalm\/jfaf044","article-title":"Plasma Cell Enrichment and New Genomic Approaches in Multiple Myeloma: A Scoping Review","volume":"10","year":"2025","journal-title":"J. Appl. Lab. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V93.12.4079","article-title":"Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage","volume":"93","author":"Szczepanski","year":"1999","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2020.11.012","article-title":"Patient-Specific Minimal Residual Disease Primers Amplify with Uniformly High Efficiency","volume":"23","author":"Latham","year":"2021","journal-title":"J. Mol. Diagn."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:32:39Z","timestamp":1786354359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":14,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167128"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167128","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]}}}